MétaCan
Menu
Back to cohort
Record W4410452393 · doi:10.1016/j.jtct.2025.05.008

Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous Transplantation

2025· article· en· W4410452393 on OpenAlexaff
Oren Pasvolsky, Curtis Marcoux, Denái R. Milton, Natalie Rafaeli, Mark R. Tanner, Qaiser Bashir, Samer A. Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Guilin Tang, Ali H. Mohamedi, Aminu Deen, Yosra Aljawai, Hans C. Lee, Krina K. Patel, Melody Becnel, Partow Kebriaei, Sheeba K. Thomas, Robert Z. Orlowski, Richard Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash

Bibliographic record

VenueTransplantation and Cellular Therapy · 2025
Typearticle
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsDalhousie University
FundersNational Cancer InstituteDr. Miriam and Sheldon G. Adelson Medical Research FoundationPaula and Rodger Riney FoundationAmerican Honda MotorUniversity of Texas MD Anderson Cancer CenterLeukemia and Lymphoma Society
KeywordsMultiple myelomaMedicineAutologous stem-cell transplantationTransplantationOncologySurgeryInternal medicine

Abstract

fetched live from OpenAlex

Upfront autologous hematopoietic cell transplantation (autoHCT) remains standard of care for eligible patients with newly diagnosed multiple myeloma (MM). Comorbidities are routinely evaluated to determine eligibility and estimate mortality after autoHCT, including the history of prior solid tumor (PST). While PST is considered high-risk for worse survival based on widely used risk indices, its independent impact on transplant outcomes in MM remains unclear. To elucidate the prognostic impact of PST in patients with MM undergoing upfront autoHCT. We conducted a single-center retrospective analysis of consecutive MM patients who underwent upfront autoHCT between 1997 and 2021, categorizing them into those with (PST+) and without (PST-) prior solid organ malignancy. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Among 2853 patients included in this analysis, 274 (10%) were PST+ and 2579 (90%) were PST-. The PST+ patients were older (67 vs. 60 years; P < .001), predominantly male (66% vs. 58%; P = .010), were more often transplanted in the year 2010 or later (78% vs. 69%; P = .003) and were more likely to have high-risk cytogenetic abnormalities (30% vs. 24%; P = .06). There was no significant difference in pre-transplant hematologic response (P = .33), day-100 post-transplant (P = .35) or the best post-transplant response (P = .27) between the PST+ and PST- groups. Similarly, there were no differences in pre-transplant (P = .34) or best post-transplant (P = .44) MRD status between the two groups. After a median follow-up of 53.8 months (range 0.2-262), the median PFS was comparable (36.7 months in PST+ vs. 39.9 months in PST-, P = .31), yet the median OS was significantly shorter in the PST+ group (81.3 months vs. 104.0 months, P = .020). Multivariable analysis confirmed PST as an independent predictor of inferior OS (HR 1.34, P = .011). MM patients undergoing upfront autoHCT with PST had worse OS compared to those without PST, despite similar response rates and PFS.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0000.001
Science and technology studies0.0010.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.274
Teacher spread0.261 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractno

Explore more

Same venueTransplantation and Cellular TherapySame topicMultiple Myeloma Research and TreatmentsFrench-language works237,207